Sterols

Valbiotis Announces the Completion of Recruitment for the Phase II HEART Clinical Study Conducted With TOTUM•070 in Hypercholesterolemia, a Risk Factor for Cardiovascular Disease

Retrieved on: 
Monday, September 6, 2021
Research, Fitness & Nutrition, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Lipids, Medical specialties, Branches of biology, Sterols, Cardiology, Lipoproteins, Lipid metabolism disorders, Low-density lipoprotein, Hypercholesterolemia, Cholesterol, Lipid-lowering agent, Phytosterol

In line with its development plan, Valbiotis confirms that the results of the HEART study will be available in the second quarter of 2022.

Key Points: 
  • In line with its development plan, Valbiotis confirms that the results of the HEART study will be available in the second quarter of 2022.
  • The HEART clinical study is a multicenter, international, randomized, placebo-controlled, double-blind study involving 120 people with untreated moderate hypercholesterolemia between 130 and 190 mg/dL.
  • The primary endpoint of the HEART study is the reduction of blood LDL-cholesterol levels, a risk factor for cardiovascular disease and in particular atherosclerosis, and it has several secondary objectives of interest.
  • The medical need is real: according to the WHO, nearly 40% of the world's adult population has high cholesterol, a well-known cardiovascular risk factor.

Marinus Pharmaceuticals Announces Exclusive Collaboration with Orion Corporation for European Commercialization of Ganaxolone

Retrieved on: 
Tuesday, August 3, 2021
Biotechnology, Pharmaceutical, Health, Chemical compounds, Anticonvulsants, GABAA receptor positive allosteric modulators, Ketones, Pregnanes, Sterols, Spacecraft, Ganaxolone, Spaceflight, Seizure, Maa, Orion, Ganaxolone, Marinus Pharmaceuticals, Orion Corporation, GANAXOLONE, MARINUS PHARMACEUTICALS, ORION CORPORATION

This collaboration not only serves as an important step in our global development strategy for ganaxolone, it also represents the confidence Orion has in its potential.

Key Points: 
  • This collaboration not only serves as an important step in our global development strategy for ganaxolone, it also represents the confidence Orion has in its potential.
  • Satu Ahomki, Senior Vice President, Commercial Operations of Orion Corporation said, We are pleased to be the partner of choice for Marinus in Europe.
  • What we have seen so far with ganaxolone is encouraging and signifies an ongoing commitment to the rare epilepsy communities.
  • Marinus expects to file a European marketing authorization application (MAA) for ganaxolone for the treatment of seizures associated with CDD by the end of Q3 2021.

Marinus Pharmaceuticals to Provide Business Update and Announce Second Quarter 2021 Financial Results on August 10, 2021

Retrieved on: 
Tuesday, August 3, 2021
Biotechnology, Mental health, Health, Pharmaceutical, Managed care, GABAA receptor positive allosteric modulators, Psychoactive drugs, Anticonvulsants, Chemical compounds, Health sciences, Ketones, Pregnanes, Sterols, CDKL5 deficiency disorder, Ganaxolone, CDKL5, Allosteric modulator

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders.

Key Points: 
  • Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders.
  • Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.
  • Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.
  • Marinus completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder last year and is conducting a Phase 2 trial in tuberous sclerosis complex and a Phase 3 trial in refractory status epilepticus.

Global Phytosterols Market (2021 to 2026) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Monday, July 5, 2021
Chemicals, Plastics, Manufacturing, Branches of biology, Phytosterol, Sterols, Cholesterol, Bioactive compound, Chemical compounds

The "Phytosterols Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Phytosterols Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global phytosterols market exhibited strong growth during 2015-2020.
  • Looking forward, the publisher expects the global phytosterols market to grow at a CAGR of around 8% during 2021-2026.
  • Phytosterols, or plant sterols, are naturally occurring bioactive compounds that are structurally similar to cholesterol found in animals.

Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences

Retrieved on: 
Friday, June 11, 2021
Research, Clinical trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Chemical compounds, GABAA receptor positive allosteric modulators, Psychoactive drugs, Anticonvulsants, Ketones, Pregnanes, Sterols, Organic compounds, Ganaxolone, Allosteric modulator, Antidepressant

Vice President, Clinical Development

Key Points: 
  • Vice President, Clinical Development
    Speakers: Scott Braunstein, M.D., Chief Executive Officer and Joe Hulihan, M.D., Chief Medical Officer
    All of the above public webcasts may be accessed through the Events & Presentations page of the Investors & Media section of the Marinus website, www.marinuspharma.com .
  • Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders.
  • Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.
  • The company has initiated a Phase 3 trial in refractory status epilepticus.

Verve Therapeutics to Present Preclinical Data from Gene Editing Programs for the Treatment of Atherosclerotic Cardiovascular Disease at ASGCT

Retrieved on: 
Tuesday, May 11, 2021
Health, Genetics, Other Health, Pharmaceutical, Cardiology, Biotechnology, Lipids, Metabolic disorders, Medical specialties, Lipid metabolism disorders, Sterols, PCSK9, Familial hypercholesterolemia, Cardiovascular diseases, Low-density lipoprotein, ANGPTL3, Hypercholesterolemia, Cholesterol

b'Verve Therapeutics , a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the presentation of additional preclinical data from the company\xe2\x80\x99s gene editing programs for the treatment of atherosclerotic cardiovascular disease (ASCVD), the most common form of cardiovascular disease, at the American Society of Gene and Cell Therapy (ASGCT) 24th Virtual Annual Meeting.

Key Points: 
  • b'Verve Therapeutics , a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the presentation of additional preclinical data from the company\xe2\x80\x99s gene editing programs for the treatment of atherosclerotic cardiovascular disease (ASCVD), the most common form of cardiovascular disease, at the American Society of Gene and Cell Therapy (ASGCT) 24th Virtual Annual Meeting.
  • In a preclinical proof-of-concept study with an ANGPTL3-gene editor administered as a single dose to NHPs, Verve observed a 95% average reduction of blood ANGPTL3 protein levels.
  • The company\xe2\x80\x99s initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease.
  • VERVE-101, currently in IND-enabling studies, is being developed initially for the treatment of patients with heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease.

Marinus Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Monday, April 12, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Anticonvulsants, GABAA receptor positive allosteric modulators, Ketones, Neurosteroids, Sterols, Chemical compounds, Ganaxolone, Chemistry

b'Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (the \xe2\x80\x9cCompany\xe2\x80\x9d or \xe2\x80\x9cMarinus\xe2\x80\x9d), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the grant of an inducement award to Steven Pfanstiel, Marinus\xe2\x80\x99 newly-hired Chief Financial Officer and Treasurer.

Key Points: 
  • b'Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (the \xe2\x80\x9cCompany\xe2\x80\x9d or \xe2\x80\x9cMarinus\xe2\x80\x9d), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the grant of an inducement award to Steven Pfanstiel, Marinus\xe2\x80\x99 newly-hired Chief Financial Officer and Treasurer.
  • The stock option was granted as an inducement material to Mr. Pfanstiel entering into employment with Marinus in accordance with Nasdaq Listing Rule 5635(c)(4), and is subject to the terms and conditions of the award agreement covering such grant.\nMarinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders.
  • Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.
  • Marinus undertakes no obligation to update or revise any forward-looking statements.

Silence Therapeutics Initiates Dosing in Phase 1 Clinical Trial of SLN360 for Cardiovascular Disease Due to High Lipoprotein(a)

Retrieved on: 
Wednesday, February 17, 2021
Lipids, Branches of biology, Cardiology, Apolipoproteins, Medical specialties, Nutrition, Sterols, Lipoproteins, Cholesterol, Atherosclerosis, High-density lipoprotein

In this case, it aims to silence LPA, a gene that tells the body to make a specific protein that is only found in Lp(a).

Key Points: 
  • In this case, it aims to silence LPA, a gene that tells the body to make a specific protein that is only found in Lp(a).
  • Lipoprotein(a), known as Lp(a) for short, is a particle made by the liver, which consists of cholesterol, fats and proteins.
  • People living with elevated Lp(a) have a higher risk of developing early heart disease, heart attacks and strokes.
  • The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made.

Marinus Pharmaceuticals to Provide Business Update and Announce Fourth Quarter and Full Year 2020 Financial Results on March 9, 2021

Retrieved on: 
Wednesday, February 10, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, GABAA receptor positive allosteric modulators, Chemical compounds, Anticonvulsants, Psychoactive drugs, Organic compounds, Ketones, Pregnanes, Sterols, Ganaxolone, Allosteric modulator

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders.

Key Points: 
  • Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders.
  • Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects.
  • Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.
  • The company is conducting a Phase 3 trial in status epilepticus.

Marinus Pharmaceuticals Provides Additional Ganaxolone Data During Scientific Exhibit at AES2020 Virtual Annual Meeting and Provides Corporate Update

Retrieved on: 
Monday, December 7, 2020
Other Health, Research, General Health, Pharmaceutical, Consumer, Children, Clinical trials, Science, Biotechnology, FDA, Other Science, Health, GABAA receptor positive allosteric modulators, Anticonvulsants, Ketones, Pregnanes, Sterols, Chemical compounds, Ganaxolone, Clinical medicine, Medicine, Status epilepticus, Seizure, Other Health, Research, General Health, Pharmaceutical, Consumer, Children, Clinical trials, Science, Biotechnology, FDA, Other Science, Health, GABAA receptor positive allosteric modulators, Anticonvulsants, Ketones, Pregnanes, Sterols, Chemical compounds, Ganaxolone, Clinical medicine, Medicine, Status epilepticus, Seizure, Ganaxolone, Marinus Pharmaceuticals

Marinus also intends to continue making ganaxolone available to clinicians who request the drug for treatment of super refractory status epilepticus on a case-by-case basis under emergency IND treatment.

Key Points: 
  • Marinus also intends to continue making ganaxolone available to clinicians who request the drug for treatment of super refractory status epilepticus on a case-by-case basis under emergency IND treatment.
  • This will provide patients with CDD access to ganaxolone under a treatment IND.
  • Marinus to Host Virtual Investor Event at AES today from 12:00 PM 2:00 PM Eastern Time.
  • Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders.